| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, ... Journal of clinical oncology 27 (32), 5410, 2009 | 850 | 2009 |
| Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United … EA Olsen, S Whittaker, YH Kim, M Duvic, HM Prince, SR Lessin, GS Wood, ... Journal of Clinical Oncology 29 (18), 2598, 2011 | 666 | 2011 |
| Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ... The Lancet 390 (10094), 555-566, 2017 | 565 | 2017 |
| Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ... The lancet oncology 19 (9), 1192-1204, 2018 | 543 | 2018 |
| Treatment outcomes of immune-related cutaneous adverse events GS Phillips, J Wu, MD Hellmann, MA Postow, NA Rizvi, A Freites-Martinez, ... Journal of Clinical Oncology 37 (30), 2746, 2019 | 192 | 2019 |
| The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients JJ Scarisbrick, P Quaglino, HM Prince, E Papadavid, E Hodak, M Bagot, ... British Journal of Dermatology 181 (2), 350-357, 2019 | 187 | 2019 |
| A review of bullous pemphigoid associated with PD‐1 and PD‐L1 inhibitors AT Lopez, T Khanna, N Antonov, C Audrey‐Bayan, L Geskin International Journal of Dermatology 57 (6), 664-669, 2018 | 172 | 2018 |
| Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation LJ Geskin, S Viragova, DB Stolz, P Fuschiotti Blood, The Journal of the American Society of Hematology 125 (18), 2798-2805, 2015 | 144 | 2015 |
| Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium P Quaglino, M Maule, HM Prince, P Porcu, S Horwitz, M Duvic, R Talpur, ... Annals of Oncology 28 (10), 2517-2525, 2017 | 139 | 2017 |
| Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy MM Johnson, SA Leachman, LG Aspinwall, LD Cranmer, ... Melanoma management 4 (1), 13-37, 2017 | 133 | 2017 |
| Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma M Duvic, EA Olsen, D Breneman, TR Pacheco, S Parker, EC Vonderheid, ... Clinical Lymphoma and Myeloma 9 (6), 412-416, 2009 | 131 | 2009 |
| CD30 expression and proliferative fraction in nontransformed mycosis fungoides JT Edinger, BZ Clark, BE Pucevich, LJ Geskin, SH Swerdlow The American journal of surgical pathology 33 (12), 1860-1868, 2009 | 130 | 2009 |
| Infectious agents in cutaneous T-cell lymphoma ED Mirvish, RG Pomerantz, LJ Geskin Journal of the American Academy of Dermatology 64 (2), 423-431, 2011 | 106 | 2011 |
| Single-cell lymphocyte heterogeneity in advanced cutaneous T-cell lymphoma skin tumors AM Gaydosik, T Tabib, LJ Geskin, CA Bayan, JF Conway, R Lafyatis, ... Clinical Cancer Research 25 (14), 4443-4454, 2019 | 103 | 2019 |
| Deep learning based on standard H&E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death PM Kulkarni, EJ Robinson, J Sarin Pradhan, RD Gartrell-Corrado, ... Clinical Cancer Research 26 (5), 1126-1134, 2020 | 99 | 2020 |
| Cutaneous T cell lymphoma R Dummer, MH Vermeer, JJ Scarisbrick, YH Kim, C Stonesifer, ... Nature Reviews Disease Primers 7 (1), 61, 2021 | 96 | 2021 |
| Breast Implant–Associated ALCL: A Unique Entity in the Spectrum of CD30+ Lymphoproliferative Disorders SK Story, MK Schowalter, LJ Geskin The Oncologist 18 (3), 301-307, 2013 | 86 | 2013 |
| Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC EA Olsen, S Whittaker, R Willemze, L Pinter-Brown, F Foss, L Geskin, ... Blood, The Journal of the American Society of Hematology 140 (5), 419-437, 2022 | 78 | 2022 |
| A case of nivolumab‐induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein‐1/programmed death ligand‐1 inhibitors and … AT Lopez, L Geskin The Oncologist 23 (10), 1119-1126, 2018 | 78 | 2018 |
| Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies JJ Mirvish, RG Pomerantz, LD Falo Jr, LJ Geskin Clinics in dermatology 31 (4), 423-431, 2013 | 76 | 2013 |
HM Prince在 petermac.org 的电子邮件经过验证
